Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2022 Aug 29:13:923286.
doi: 10.3389/fimmu.2022.923286. eCollection 2022.

Efficacy of umbilical cord mesenchymal stromal cells for COVID-19: A systematic review and meta-analysis

Cong-Wen Yang  1 , Ru-Dong Chen  2 , Qing-Run Zhu  2 , Shi-Jie Han  2 , Ming-Jie Kuang  2
Affiliations
Meta-Analysis

Efficacy of umbilical cord mesenchymal stromal cells for COVID-19: A systematic review and meta-analysis

Cong-Wen Yang et al. Front Immunol. .

Erratum in

Abstract

Objectives: A major challenge for COVID-19 therapy is dysregulated immune response associated with the disease. Umbilical cord mesenchymal stromal cells (UC-MSCs) may be a promising candidate for COVID-19 treatment owing to their immunomodulatory and anti-inflammatory functions. Therefore, this study aimed to evaluate the effectiveness of UC-MSCs inpatients with COVID-19.

Method: Medline, Embase, PubMed, Cochrane Library, and Web of Science databases were searched to collect clinical trials concerning UC-MSCs for the treatment of COVID-19. After literature screening, quality assessment, and data extraction, a systematic review and meta-analysis of the included study were performed.

Results: This systematic review and meta-analysis were prospectively registered on PROSPERO, and the registration number is CRD42022304061. After screening, 10 studies involving 293 patients with COVID-19 were eventually included. Our meta-analysis results showed that UC-MSCs can reduce mortality (relative risk [RR] =0.60, 95% confidence interval [CI]: [0.38, 0.95], P=0.03) in COVID-19 patients. No significant correlation was observed between adverse events and UC-MSC treatment (RR=0.85, 95% CI: [0.65, 1.10], P=0.22; RR=1.00, 95%CI: [0.64, 1.58], P=1.00). In addition, treatment with UC-MSCs was found to suppress inflammation and improve pulmonary symptoms.

Conclusions: UC-MSCs hold promise as a safe and effective treatment for COVID-19.

Systematic review registartion: PROSPERO, identifier CRD42022304061.

Keywords: COVID-19; adverse events and severe adverse events; immunomodulation; the Mortality rate,; umbilical cord mesenchymal stromal cells (UC-MSCs).

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
PRISMA 2020 flow diagram. A total of 111 records were retrieved, after inclusion and exclusion criteria, the final 10 studies were included.
Figure 2
Figure 2
The effect of UC-MSCs therapy by forest plot diagram on COVID-19 mortality rate.
Figure 3
Figure 3
The effect of UC-MSCs therapy by forest plot diagram on AEs and SAEs. (A) The number of patients experiencing AEs and SAEs; (B) The number of types of AEs and SAEs.
Figure 4
Figure 4
The effect of UC-MSCs therapy by forest plot diagram on the number of patients requiring respiratory support (A), duration of oxygen therapy (B), and hospital stay (C).
Figure 5
Figure 5
The results of funnel plot (A) mortality rate; (B) patients experiencing AEs and SAEs; (C) types of AEs and SAEs; (D) patients requiring respiratory support; (E) duration of oxygen therapy; (F) hospital stay.
See this image and copyright information in PMC

References

    1. Kim YC, Jeong BH. Strong correlation between the case fatality rate of COVID-19 and the rs6598045 single nucleotide polymorphism (SNP) of the interferon-induced transmembrane protein 3 (IFITM3) gene at the population-level. Genes (Basel) (2020) 12(1):42. doi: 10.3390/genes12010042 - DOI - PMC - PubMed
    1. Cascella M, Rajnik M, Aleem A, Dulebohn SC, Di Napoli R. Features, evaluation, and treatment of coronavirus (COVID-19). In: StatPearls. Treasure Island (FL: StatPearls Publishing Copyright © 2022, StatPearls Publishing LLC; (2022). - PubMed
    1. COVID-ICU Group on behalf of the REVA Network and the COVID-ICU Investigators . Clinical characteristics and day-90 outcomes of 4244 critically ill adults with COVID-19: A prospective cohort study. Intensive Care Med (2021) 47(1):60–73. doi: 10.1007/s00134-020-06294-x - DOI - PMC - PubMed
    1. Girija ASS, Shankar EM, Larsson M. Could SARS-CoV-2-Induced hyperinflammation magnify the severity of coronavirus disease (CoViD-19) leading to acute respiratory distress syndrome? Front Immunol (2020) 11:1206. doi: 10.3389/fimmu.2020.01206 - DOI - PMC - PubMed
    1. Chauhan AJ, Wiffen LJ, Brown TP. COVID-19: A collision of complement, coagulation and inflammatory pathways. J Thromb Haemost (2020) 18(9):2110–7. doi: 10.1111/jth.14981 - DOI - PMC - PubMed

Publication types